October 13, 2020
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating an Amgen unit's patent on treating inflammatory disorders, in a win for Sanofi and Regeneron, whose eczema and asthma treatment Dupixent was accused of infringement.
August 05, 2020
A Federal Circuit panel appeared skeptical Wednesday that the Patent Trial and Appeal Board ignored vital evidence in construing a key claim term to invalidate an Immunex antibody patent at the behest of Sanofi-Aventis, suggesting that evidence supports the board's claim construction.